| DIRECT COMPETITOR COMPARISON | |
| ASTM | BAX | CYTX | JNJ | Industry | | Market Cap: | 50.45M | 33.01B | 191.44M | 174.65B | 94.68M | | Employees: | 48 | 48,500 | 126 | 118,700 | 65 | | Qtrly Rev Growth (yoy): | 170.40% | -0.20% | -40.00% | -5.30% | 19.70% | | Revenue (ttm): | 228.00K | 12.22B | 14.01M | 60.53B | 14.05M | | Gross Margin (ttm): | 38.60% | 51.23% | 90.75% | 71.08% | 64.07% | | EBITDA (ttm): | -15.29M | 3.37B | -15.20M | 19.05B | -12.30M | | Oper Margins (ttm): | -7,002.63% | 22.54% | -120.28% | 26.94% | -124.89% | | Net Income (ttm): | -15.83M | 2.20B | -20.26M | 12.77B | N/A | | EPS (ttm): | -0.105 | 3.562 | -0.605 | 4.579 | -0.32 | | P/E (ttm): | N/A | 15.37 | N/A | 13.82 | 17.01 | | PEG (5 yr expected): | N/A | 1.26 | N/A | 1.86 | 1.31 | | P/S (ttm): | 223.80 | 2.72 | 13.67 | 2.88 | 9.57 |
|
| BAX = Baxter International Inc. | | CYTX = Cytori Therapeutics, Inc. | | JNJ = Johnson & Johnson | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | JNJ | | Theravance, Inc.: Wait to Buy on Dip
Thu 6:19am -
at Seeking Alpha | | • | JNJ | | Health Care Winners
Thu 6:06am -
at Forbes.com | | • | BAX | | 10 Dividend Picks For Your Portfolio: Chief Investors
Wed 6:34pm -
at CNBC | | • | JNJ | | FDA grants full approval to J&J's HIV drug
Wed 4:07pm -
AP | | • | BAX | | [video] The Dividend Strategy
Wed 3:45pm -
at CNBC | | • | JNJ | | Turning to Widow and Orphan Stocks
Wed 3:36pm -
at Barrons.com | | • | JNJ | | Novartis Didn't Know JAK, Until Now
Wed 2:41pm -
at Motley Fool | | • | JNJ | | S&P Stocks Trading at New 52-Week Highs
Wed 12:44pm -
at CNBC | | • | BAX | | Becton Acquires HandyLab
Mon, Nov 23 -
Zacks.com | | • | BAX | | 30 High Yielding Option Write Ideas for November Option Expiration Friday
Fri, Nov 20 -
at Seeking Alpha | | • | BAX | | Healthcare Spin Off Companies Offer Opportunity To Investors According To Credit Suisse Senior Analyst
Thu, Nov 19 -
Wall Street Transcript | | • | BAX | | Sector Snap: UBS upbeat on medical tech stocks
Wed, Nov 18 -
AP | | • | BAX | | Coverage initiated on Baxter by Morgan Keegan
Wed, Nov 18 -
Briefing.com | | • | CYTX | | BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
Tue, Nov 17 -
at Seeking Alpha | | • | CYTX | | Cytori Completes Enrollment in International Breast Cancer Reconstruction Study; Interim Data to Be Presented Dec. 12 at San Antonio Breast Cancer Symposium
Mon, Nov 16 -
Business Wire | | • | CYTX | | CYTORI THERAPEUTICS, INC. Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | CYTX | | Cytori Therapeutics Q3 2009 Earnings Call Transcript
Mon, Nov 9 -
at Seeking Alpha | | • | CYTX | | 5-Star Stocks on the Upswing
Mon, Nov 9 -
at Motley Fool | | • | CYTX | | Cytori Therapeutics 3rd Qtr Results Call scheduled for 10:30 am ET today
Mon, Nov 9 -
Shareholder.com | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
0.00 (1.13%) 
Competitors
